In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Michael Pfeilstöcker discusses newer therapeutic agents for use in the treatment of myelodysplastic syndromes (MDS) when hypomethylating agents (HMAs) fail.
A continuing education program related to this video is offered at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7210
© 2016 Imedex, LLC.
Advertisement